Then, they used immunoprecipitation in colon cancer cell lines, and found in the FOXN3 antibody-positive results that the capability of TCF4 to form complexes with β-catenin was weaker than in the FOXN3 antibody-negative results, showing that FOXN3 inhibits the catenin/TCF signaling pathway by blocking the binding between β-catenin and TCF4. This evidence concerns the gene FOXN3 and malignant colon neoplasm.